Standard

Cell-free expression of sodium channel domains for pharmacology studies. Noncanonical spider toxin binding site in the second voltage-sensing domain of human Nav1.4 channel. / Myshkin, Mikhail Yu; Männikkö, Roope; Krumkacheva, Olesya A. et al.

In: Frontiers in Pharmacology, Vol. 10, 953, 04.09.2019.

Research output: Contribution to journalArticlepeer-review

Harvard

Myshkin, MY, Männikkö, R, Krumkacheva, OA, Kulbatskii, DS, Chugunov, AO, Berkut, AA, Paramonov, AS, Shulepko, MA, Fedin, MV, Hanna, MG, Kullmann, DM, Bagryanskaya, EG, Arseniev, AS, Kirpichnikov, MP, Lyukmanova, EN, Vassilevski, AA & Shenkarev, ZO 2019, 'Cell-free expression of sodium channel domains for pharmacology studies. Noncanonical spider toxin binding site in the second voltage-sensing domain of human Nav1.4 channel', Frontiers in Pharmacology, vol. 10, 953. https://doi.org/10.3389/fphar.2019.00953

APA

Myshkin, M. Y., Männikkö, R., Krumkacheva, O. A., Kulbatskii, D. S., Chugunov, A. O., Berkut, A. A., Paramonov, A. S., Shulepko, M. A., Fedin, M. V., Hanna, M. G., Kullmann, D. M., Bagryanskaya, E. G., Arseniev, A. S., Kirpichnikov, M. P., Lyukmanova, E. N., Vassilevski, A. A., & Shenkarev, Z. O. (2019). Cell-free expression of sodium channel domains for pharmacology studies. Noncanonical spider toxin binding site in the second voltage-sensing domain of human Nav1.4 channel. Frontiers in Pharmacology, 10, [953]. https://doi.org/10.3389/fphar.2019.00953

Vancouver

Myshkin MY, Männikkö R, Krumkacheva OA, Kulbatskii DS, Chugunov AO, Berkut AA et al. Cell-free expression of sodium channel domains for pharmacology studies. Noncanonical spider toxin binding site in the second voltage-sensing domain of human Nav1.4 channel. Frontiers in Pharmacology. 2019 Sept 4;10:953. doi: 10.3389/fphar.2019.00953

Author

BibTeX

@article{998aff0f9c544a229b38035c25caba06,
title = "Cell-free expression of sodium channel domains for pharmacology studies. Noncanonical spider toxin binding site in the second voltage-sensing domain of human Nav1.4 channel",
abstract = "Voltage-gated sodium (NaV) channels are essential for the normal functioning of cardiovascular, muscular, and nervous systems. These channels have modular organization; the central pore domain allows current flow and provides ion selectivity, whereas four peripherally located voltage-sensing domains (VSDs-I/IV) are needed for voltage-dependent gating. Mutations in the S4 voltage-sensing segments of VSDs in the skeletal muscle channel NaV1.4 trigger leak (gating pore) currents and cause hypokalemic and normokalemic periodic paralyses. Previously, we have shown that the gating modifier toxin Hm-3 from the crab spider Heriaeus melloteei binds to the S3-S4 extracellular loop in VSD-I of NaV1.4 channel and inhibits gating pore currents through the channel with mutations in VSD-I. Here, we report that Hm-3 also inhibits gating pore currents through the same channel with the R675G mutation in VSD-II. To investigate the molecular basis of Hm-3 interaction with VSD-II, we produced the corresponding 554-696 fragment of NaV1.4 in a continuous exchange cell-free expression system based on the Escherichia coli S30 extract. We then performed a combined nuclear magnetic resonance (NMR) and electron paramagnetic resonance spectroscopy study of isolated VSD-II in zwitterionic dodecylphosphocholine/ lauryldimethylamine-N-oxide or dodecylphosphocholine micelles. To speed up the assignment of backbone resonances, five selectively 13C,15N-labeled VSD-II samples were produced in accordance with specially calculated combinatorial scheme. This labeling approach provides assignment for ~50% of the backbone. Obtained NMR and electron paramagnetic resonance data revealed correct secondary structure, quasi-native VSD-II fold, and enhanced ps-ns timescale dynamics in the micelle-solubilized domain. We modeled the structure of the VSD-II/Hm-3 complex by protein-protein docking involving binding surfaces mapped by NMR. Hm-3 binds to VSDs I and II using different modes. In VSD-II, the protruding β-hairpin of Hm-3 interacts with the S1-S2 extracellular loop, and the complex is stabilized by ionic interactions between the positively charged toxin residue K24 and the negatively charged channel residues E604 or D607. We suggest that Hm-3 binding to these charged groups inhibits voltage sensor transition to the activated state and blocks the depolarization-activated gating pore currents. Our results indicate that spider toxins represent a useful hit for periodic paralyses therapy development and may have multiple structurally different binding sites within one NaV molecule.",
keywords = "Cell-free expression, Channelopathies, Combinatorial selective labeling, Gating modifier, Ligand-receptor interactions, NMR spectroscopy, Sodium channel, PERIODIC PARALYSIS, channelopathies, ligand-receptor interactions, combinatorial selective labeling, DETERGENT MICELLES, cell-free expression, gating modifier, sodium channel, GATING PORE CURRENTS, MUTATIONS, BACKBONE, LIPID-PROTEIN NANODISCS, COMPREHENSIVE SOFTWARE PACKAGE, TOOL",
author = "Myshkin, {Mikhail Yu} and Roope M{\"a}nnikk{\"o} and Krumkacheva, {Olesya A.} and Kulbatskii, {Dmitrii S.} and Chugunov, {Anton O.} and Berkut, {Antonina A.} and Paramonov, {Alexander S.} and Shulepko, {Mikhail A.} and Fedin, {Matvey V.} and Hanna, {Michael G.} and Kullmann, {Dimitri M.} and Bagryanskaya, {Elena G.} and Arseniev, {Alexander S.} and Kirpichnikov, {Mikhail P.} and Lyukmanova, {Ekaterina N.} and Vassilevski, {Alexander A.} and Shenkarev, {Zakhar O.}",
year = "2019",
month = sep,
day = "4",
doi = "10.3389/fphar.2019.00953",
language = "English",
volume = "10",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S.A.",

}

RIS

TY - JOUR

T1 - Cell-free expression of sodium channel domains for pharmacology studies. Noncanonical spider toxin binding site in the second voltage-sensing domain of human Nav1.4 channel

AU - Myshkin, Mikhail Yu

AU - Männikkö, Roope

AU - Krumkacheva, Olesya A.

AU - Kulbatskii, Dmitrii S.

AU - Chugunov, Anton O.

AU - Berkut, Antonina A.

AU - Paramonov, Alexander S.

AU - Shulepko, Mikhail A.

AU - Fedin, Matvey V.

AU - Hanna, Michael G.

AU - Kullmann, Dimitri M.

AU - Bagryanskaya, Elena G.

AU - Arseniev, Alexander S.

AU - Kirpichnikov, Mikhail P.

AU - Lyukmanova, Ekaterina N.

AU - Vassilevski, Alexander A.

AU - Shenkarev, Zakhar O.

PY - 2019/9/4

Y1 - 2019/9/4

N2 - Voltage-gated sodium (NaV) channels are essential for the normal functioning of cardiovascular, muscular, and nervous systems. These channels have modular organization; the central pore domain allows current flow and provides ion selectivity, whereas four peripherally located voltage-sensing domains (VSDs-I/IV) are needed for voltage-dependent gating. Mutations in the S4 voltage-sensing segments of VSDs in the skeletal muscle channel NaV1.4 trigger leak (gating pore) currents and cause hypokalemic and normokalemic periodic paralyses. Previously, we have shown that the gating modifier toxin Hm-3 from the crab spider Heriaeus melloteei binds to the S3-S4 extracellular loop in VSD-I of NaV1.4 channel and inhibits gating pore currents through the channel with mutations in VSD-I. Here, we report that Hm-3 also inhibits gating pore currents through the same channel with the R675G mutation in VSD-II. To investigate the molecular basis of Hm-3 interaction with VSD-II, we produced the corresponding 554-696 fragment of NaV1.4 in a continuous exchange cell-free expression system based on the Escherichia coli S30 extract. We then performed a combined nuclear magnetic resonance (NMR) and electron paramagnetic resonance spectroscopy study of isolated VSD-II in zwitterionic dodecylphosphocholine/ lauryldimethylamine-N-oxide or dodecylphosphocholine micelles. To speed up the assignment of backbone resonances, five selectively 13C,15N-labeled VSD-II samples were produced in accordance with specially calculated combinatorial scheme. This labeling approach provides assignment for ~50% of the backbone. Obtained NMR and electron paramagnetic resonance data revealed correct secondary structure, quasi-native VSD-II fold, and enhanced ps-ns timescale dynamics in the micelle-solubilized domain. We modeled the structure of the VSD-II/Hm-3 complex by protein-protein docking involving binding surfaces mapped by NMR. Hm-3 binds to VSDs I and II using different modes. In VSD-II, the protruding β-hairpin of Hm-3 interacts with the S1-S2 extracellular loop, and the complex is stabilized by ionic interactions between the positively charged toxin residue K24 and the negatively charged channel residues E604 or D607. We suggest that Hm-3 binding to these charged groups inhibits voltage sensor transition to the activated state and blocks the depolarization-activated gating pore currents. Our results indicate that spider toxins represent a useful hit for periodic paralyses therapy development and may have multiple structurally different binding sites within one NaV molecule.

AB - Voltage-gated sodium (NaV) channels are essential for the normal functioning of cardiovascular, muscular, and nervous systems. These channels have modular organization; the central pore domain allows current flow and provides ion selectivity, whereas four peripherally located voltage-sensing domains (VSDs-I/IV) are needed for voltage-dependent gating. Mutations in the S4 voltage-sensing segments of VSDs in the skeletal muscle channel NaV1.4 trigger leak (gating pore) currents and cause hypokalemic and normokalemic periodic paralyses. Previously, we have shown that the gating modifier toxin Hm-3 from the crab spider Heriaeus melloteei binds to the S3-S4 extracellular loop in VSD-I of NaV1.4 channel and inhibits gating pore currents through the channel with mutations in VSD-I. Here, we report that Hm-3 also inhibits gating pore currents through the same channel with the R675G mutation in VSD-II. To investigate the molecular basis of Hm-3 interaction with VSD-II, we produced the corresponding 554-696 fragment of NaV1.4 in a continuous exchange cell-free expression system based on the Escherichia coli S30 extract. We then performed a combined nuclear magnetic resonance (NMR) and electron paramagnetic resonance spectroscopy study of isolated VSD-II in zwitterionic dodecylphosphocholine/ lauryldimethylamine-N-oxide or dodecylphosphocholine micelles. To speed up the assignment of backbone resonances, five selectively 13C,15N-labeled VSD-II samples were produced in accordance with specially calculated combinatorial scheme. This labeling approach provides assignment for ~50% of the backbone. Obtained NMR and electron paramagnetic resonance data revealed correct secondary structure, quasi-native VSD-II fold, and enhanced ps-ns timescale dynamics in the micelle-solubilized domain. We modeled the structure of the VSD-II/Hm-3 complex by protein-protein docking involving binding surfaces mapped by NMR. Hm-3 binds to VSDs I and II using different modes. In VSD-II, the protruding β-hairpin of Hm-3 interacts with the S1-S2 extracellular loop, and the complex is stabilized by ionic interactions between the positively charged toxin residue K24 and the negatively charged channel residues E604 or D607. We suggest that Hm-3 binding to these charged groups inhibits voltage sensor transition to the activated state and blocks the depolarization-activated gating pore currents. Our results indicate that spider toxins represent a useful hit for periodic paralyses therapy development and may have multiple structurally different binding sites within one NaV molecule.

KW - Cell-free expression

KW - Channelopathies

KW - Combinatorial selective labeling

KW - Gating modifier

KW - Ligand-receptor interactions

KW - NMR spectroscopy

KW - Sodium channel

KW - PERIODIC PARALYSIS

KW - channelopathies

KW - ligand-receptor interactions

KW - combinatorial selective labeling

KW - DETERGENT MICELLES

KW - cell-free expression

KW - gating modifier

KW - sodium channel

KW - GATING PORE CURRENTS

KW - MUTATIONS

KW - BACKBONE

KW - LIPID-PROTEIN NANODISCS

KW - COMPREHENSIVE SOFTWARE PACKAGE

KW - TOOL

UR - http://www.scopus.com/inward/record.url?scp=85072937673&partnerID=8YFLogxK

U2 - 10.3389/fphar.2019.00953

DO - 10.3389/fphar.2019.00953

M3 - Article

C2 - 31555136

AN - SCOPUS:85072937673

VL - 10

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

M1 - 953

ER -

ID: 22849004